Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model

References

• Robain M, Pierga JY, Jouve M, Asselain B, Dieras V, Beuzeboc P, et al. Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer. Eur J Cancer 2000; 36: 2301–12
   PubMed Web of Science ®Google Scholar
• Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005; 46: 1144–50
   PubMed Web of Science ®Google Scholar
• Pusztai L, Asmar L, Smith TL, Hortobagyi GN. Relapse after complete response to anthracycline-based combination chemotherapy in metastatic breast cancer. Breast Cancer Res Treat 1999; 55: 1–8
   PubMed Web of Science ®Google Scholar
• Martin, M. Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2001;2:190–208; Discussion 209.
   PubMedGoogle Scholar
• Vassilomanolakis M, Koumakis G, Barbounis V, Demiri M, Panopoulos C, Chrissohoou M, et al. First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer. Breast 2005; 14: 136–41
   PubMed Web of Science ®Google Scholar
• Vassilomanolakis M, Koumakis G, Barbounis V, Demiri M, Pateras H, Efremidis AP. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. Ann Oncol 2000; 11: 1155–60
   PubMed Web of Science ®Google Scholar
• Rosati G, Riccardi F, Tucci A, De Rosa P, Pacilio G. A phase II study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy. Tumori 2000; 86: 207–10
   PubMed Web of Science ®Google Scholar
• Vassilomanolakis M, Koumakis G, Demiri M, Missitzis J, Barbounis V, Efremidis AP. Vinorelbine and cisplatin for metastatic breast cancer: A salvage regimen in patients progressing after docetaxel and anthracycline treatment. Cancer Invest 2003; 21: 497–504
   PubMed Web of Science ®Google Scholar
• Moriuchi S, Shimizu K, Miyao Y, Yumada M, Ohkawa M, Hayakawa T. In vitro assessment for neurotoxicity of antitumor agents before local administration into central nervous system. Anticancer Res 1996; 16: 135–40
   PubMed Web of Science ®Google Scholar
• Schondorf T, Kurbacher CM, Gohring UJ, Benz C, Becker M, Sartorius J, et al. Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines. Anticancer Res 2002; 22: 2199–203
   PubMed Web of Science ®Google Scholar
• Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B, Pinedo HM. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991; 27: 897–900
   PubMed Web of Science ®Google Scholar
• Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis RW. Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci USA 1996; 93: 10614–9
   PubMed Web of Science ®Google Scholar
• Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45
   PubMed Web of Science ®Google Scholar
• Iwasaki I, Sugiyama H, Kanazawa S, Hemmi H. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles. Cancer Chemother Pharmacol 2002; 49: 438–44
   PubMed Web of Science ®Google Scholar
• Liby K, Neltner B, Mohamet L, Menchen L, Ben-Jonathan N. Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Res Treat 2003; 79: 241–52
   PubMed Web of Science ®Google Scholar
• Alberts GF, Peifley KA, Johns A, Kleha JF, Winkles JA. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem 1994; 269: 10112–8
   PubMed Web of Science ®Google Scholar
• Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer 2004; 91: 305–11
   PubMed Web of Science ®Google Scholar
• Ogretmen B, Hannun YA. Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resist Updat 2001; 4: 368–77
   PubMed Web of Science ®Google Scholar
• Porter LA, Cukier IH, Lee JM. Nuclear localization of cyclin B1 regulates DNA damage-induced apoptosis. Blood 2003; 101: 1928–33
   PubMed Web of Science ®Google Scholar
• Wang HY, Cheng Z, Malbon CC. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 2003; 191: 229–37
   PubMed Web of Science ®Google Scholar
• Guan KL, Butch E. Isolation and characterization of a novel dual specific phosphatase, HVH2, which selectively dephosphorylates the mitogen-activated protein kinase. J Biol Chem 1995; 270: 7197–203
   PubMed Web of Science ®Google Scholar
• Shimizu F, Watanabe TK, Okuno S, Omori Y, Fujiwara T, Takahashi E, et al. Isolation of a novel human cDNA (rhoHP1) homologous to rho genes. Biochim Biophys Acta 1997; 1351: 13–6
   PubMed Web of Science ®Google Scholar
• Subauste MC, Von Herrath M, Benard V, Chamberlain CE, Chuang TH, Chu K, et al. Rho family proteins modulate rapid apoptosis induced by cytotoxic T lymphocytes and Fas. J Biol Chem 2000; 275: 9725–33
   PubMed Web of Science ®Google Scholar
• Black SM, Beggs JD, Hayes JD, Bartoszek A, Muramatsu M, Sakai M, et al. Expression of human glutathione S-transferases in Saccharomyces cerevisiae confers resistance to the anticancer drugs adriamycin and chlorambucil. Biochem J 1990; 268: 309–15
   PubMed Web of Science ®Google Scholar
• Townsend AJ, Tu CP, Cowan KH. Expression of human mu or alpha class glutathione S-transferases in stably transfected human MCF-7 breast cancer cells: Effect on cellular sensitivity to cytotoxic agents. Mol Pharmacol 1992; 41: 230–6
   PubMed Web of Science ®Google Scholar